- •Preface to the 3rd edition
- •General Pharmacology
- •Systems Pharmacology
- •Therapy of Selected Diseases
- •Subject Index
- •Abbreviations
- •General Pharmacology
- •History of Pharmacology
- •Drug and Active Principle
- •The Aims of Isolating Active Principles
- •European Plants as Sources of Effective Medicines
- •Drug Development
- •Congeneric Drugs and Name Diversity
- •Oral Dosage Forms
- •Drug Administration by Inhalation
- •Dermatological Agents
- •From Application to Distribution in the Body
- •Potential Targets of Drug Action
- •External Barriers of the Body
- •Blood–Tissue Barriers
- •Membrane Permeation
- •Binding to Plasma Proteins
- •The Liver as an Excretory Organ
- •Biotransformation of Drugs
- •Drug Metabolism by Cytochrome P450
- •The Kidney as an Excretory Organ
- •Presystemic Elimination
- •Drug Concentration in the Body as a Function of Time—First Order (Exponential) Rate Processes
- •Time Course of Drug Concentration in Plasma
- •Time Course of Drug Plasma Levels during Repeated Dosing (A)
- •Time Course of Drug Plasma Levels during Irregular Intake (B)
- •Accumulation: Dose, Dose Interval, and Plasma Level Fluctuation (A)
- •Dose–Response Relationship
- •Concentration–Effect Curves (B)
- •Concentration–Binding Curves
- •Types of Binding Forces
- •Agonists—Antagonists
- •Other Forms of Antagonism
- •Enantioselectivity of Drug Action
- •Receptor Types
- •Undesirable Drug Effects, Side Effects
- •Drug Allergy
- •Cutaneous Reactions
- •Drug Toxicity in Pregnancy and Lactation
- •Pharmacogenetics
- •Placebo (A)
- •Systems Pharmacology
- •Sympathetic Nervous System
- •Structure of the Sympathetic Nervous System
- •Adrenergic Synapse
- •Adrenoceptor Subtypes and Catecholamine Actions
- •Smooth Muscle Effects
- •Cardiostimulation
- •Metabolic Effects
- •Structure–Activity Relationships of Sympathomimetics
- •Indirect Sympathomimetics
- •Types of
- •Antiadrenergics
- •Parasympathetic Nervous System
- •Cholinergic Synapse
- •Parasympathomimetics
- •Parasympatholytics
- •Actions of Nicotine
- •Localization of Nicotinic ACh Receptors
- •Effects of Nicotine on Body Function
- •Aids for Smoking Cessation
- •Consequences of Tobacco Smoking
- •Dopamine
- •Histamine Effects and Their Pharmacological Properties
- •Serotonin
- •Vasodilators—Overview
- •Organic Nitrates
- •Calcium Antagonists
- •ACE Inhibitors
- •Drugs Used to Influence Smooth Muscle Organs
- •Cardiac Drugs
- •Cardiac Glycosides
- •Antiarrhythmic Drugs
- •Drugs for the Treatment of Anemias
- •Iron Compounds
- •Prophylaxis and Therapy of Thromboses
- •Possibilities for Interference (B)
- •Heparin (A)
- •Hirudin and Derivatives (B)
- •Fibrinolytics
- •Intra-arterial Thrombus Formation (A)
- •Formation, Activation, and Aggregation of Platelets (B)
- •Inhibitors of Platelet Aggregation (A)
- •Presystemic Effect of ASA
- •Plasma Volume Expanders
- •Lipid-lowering Agents
- •Diuretics—An Overview
- •NaCl Reabsorption in the Kidney (A)
- •Aquaporins (AQP)
- •Osmotic Diuretics (B)
- •Diuretics of the Sulfonamide Type
- •Potassium-sparing Diuretics (A)
- •Vasopressin and Derivatives (B)
- •Drugs for Gastric and Duodenal Ulcers
- •Laxatives
- •Antidiarrheal Agents
- •Drugs Affecting Motor Function
- •Muscle Relaxants
- •Nondepolarizing Muscle Relaxants
- •Depolarizing Muscle Relaxants
- •Antiparkinsonian Drugs
- •Antiepileptics
- •Pain Mechanisms and Pathways
- •Eicosanoids
- •Antipyretic Analgesics
- •Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- •Cyclooxygenase (COX) Inhibitors
- •Local Anesthetics
- •Opioid Analgesics—Morphine Type
- •General Anesthesia and General Anesthetic Drugs
- •Inhalational Anesthetics
- •Injectable Anesthetics
- •Sedatives, Hypnotics
- •Benzodiazepines
- •Pharmacokinetics of Benzodiazepines
- •Therapy of Depressive Illness
- •Mania
- •Therapy of Schizophrenia
- •Psychotomimetics (Psychedelics, Hallucinogens)
- •Hypothalamic and Hypophyseal Hormones
- •Thyroid Hormone Therapy
- •Glucocorticoid Therapy
- •Follicular Growth and Ovulation, Estrogen and Progestin Production
- •Oral Contraceptives
- •Antiestrogen and Antiprogestin Active Principles
- •Aromatase Inhibitors
- •Insulin Formulations
- •Treatment of Insulin-dependent Diabetes Mellitus
- •Treatment of Maturity-Onset (Type II) Diabetes Mellitus
- •Oral Antidiabetics
- •Drugs for Maintaining Calcium Homeostasis
- •Drugs for Treating Bacterial Infections
- •Inhibitors of Cell Wall Synthesis
- •Inhibitors of Tetrahydrofolate Synthesis
- •Inhibitors of DNA Function
- •Inhibitors of Protein Synthesis
- •Drugs for Treating Mycobacterial Infections
- •Drugs Used in the Treatment of Fungal Infections
- •Chemotherapy of Viral Infections
- •Drugs for the Treatment of AIDS
- •Drugs for Treating Endoparasitic and Ectoparasitic Infestations
- •Antimalarials
- •Other Tropical Diseases
- •Chemotherapy of Malignant Tumors
- •Targeting of Antineoplastic Drug Action (A)
- •Mechanisms of Resistance to Cytostatics (B)
- •Inhibition of Immune Responses
- •Antidotes and Treatment of Poisonings
- •Therapy of Selected Diseases
- •Hypertension
- •Angina Pectoris
- •Antianginal Drugs
- •Acute Coronary Syndrome— Myocardial Infarction
- •Congestive Heart Failure
- •Hypotension
- •Gout
- •Obesity—Sequelae and Therapeutic Approaches
- •Osteoporosis
- •Rheumatoid Arthritis
- •Migraine
- •Common Cold
- •Atopy and Antiallergic Therapy
- •Bronchial Asthma
- •Emesis
- •Alcohol Abuse
- •Local Treatment of Glaucoma
- •Further Reading
- •Further Reading
- •Picture Credits
- •Drug Indexes
342 Therapy of Selected Diseases
Emesis
In emesis the stomach empties in a retrograde manner. The pyloric sphincter is closed while cardia and esophagus relax to allow gastric contents to be propelled orad by a forceful synchronous contraction of abdominal wall muscles and diaphragm. Closure of the glottis and elevation of the soft palate prevent entry of vomitus into the trachea and the nasopharynx. As a rule, there is prodromal salivation or yawning. Coordination between these different stages depends on the medullary center for emesis, which can be activated by diverse stimuli. These are conveyed via the vestibular apparatus, visual, olfactory, and gustatory inputs, as well as viscerosensory afferents from the upper alimentary tract. Psychic stress may also activate the emetic center. The mechanisms underlying motion sickness (kinetosis, sea sickness) and vomiting during pregnancy are still unclear.
Polar substances cannot reach the emetic center itself because it is protected by the blood–brain barrier. However, they can indirectly excite the center by activating chemoreceptors in the area postrema or receptors on peripheral vagal nerve endings.
Antiemetic therapy. Vomiting can be a useful reaction enabling the body to eliminate an orally ingested poison. Antiemetic drugs are used to prevent kinetosis, pregnancy vomiting, cytotoxic drug-induced or postoperative vomiting, as well as vomiting due to radiation therapy.
Motion sickness. Effective prophylaxis can be achieved with the parasympatholytic scopolamine (p.110) and H1-antihistaminics (p.118) of the diphenylmethane type (e. g., diphenhydramine, meclizine). Antiemetic activity is not a property shared by all parasympatholytics or antihistaminics. The ef - cacy of the drugs mentioned depends on the actual situation of the individual (gastric filling, ethanol consumption), environmental conditions (e. g., the behavior of fellow trav-
elers), and the type of motion experienced. The drugs should be taken 30 minutes before the start of travel and repeated every 4–6 hours. Scopolamine applied transdermally through an adhesive patch 6–8 hours before travel can provide effective protection for up to 3 days.
Pregnancy vomiting is prone to occur in the first trimester; thus, pharmacotherapy would coincide with the period of maximal fetal vulnerability to chemical injury. Accordingly, antiemetics (antihistaminics, or neuroleptics if required; p. 232) should be used only when continuous vomiting threatens to disturb electrolyte and water balance to a degree that places the fetus at risk.
Drug-induced vomiting. To prevent vomiting during anticancer chemotherapy (especially, with cisplatin), effective use can be made of 5-HT3 receptor antagonists (e. g., ondansetron, granisetron, and tropisetron), alone or in combination with glucocorticoids (methylprednisolone, dexamethasone). Anticipatory nausea and vomiting, resulting from inadequately controlled nausea and emesis in patients undergoing cytotoxic chemotherapy, can be attenuated by a benzodiazepine such as lorazepam. Dopamine ag- onist-induced nausea in parkinsonian patients (p.188) can be counteracted with D2- receptor antagonists that penetrate poorly into the CNS (e. g., domperidone, sulpiride).
Metoclopramide is effective in nausea and vomiting of gastrointestinal origin (5-HT4 receptor agonism) and at high dosage also in chemotherapy- and radiation-induced sickness (low potency antagonism at 5-HT3 and D3-receptors). Phenothiazines (e. g., levomepromazine, trimeprazine, and perphenazine) or metoclopramide may suppress nausea/emesis that follows certain types of surgery or is due to opioid analgesics, gastrointestinal irritation, uremia, and diseases accompanied by elevated intracranial pressure.
The synthetic cannabinoids dronabinol and nabilone have antiemetic effects that may benefit AIDS and cancer patients.
Emesis 343
A. Emetic stimuli and antiemetic drugs
Kinetoses
e.g., sea sickness
Pregnancy
vomiting
Chemoreceptors
Emetic center
Psychogenic vomiting
Sight |
|
|
|
Vestibular |
Area postrema |
Olfaction |
system |
|
|
|
|
Taste |
|
Chemoreceptors |
|
|
(drug-induced |
|
|
vomiting) |
Intramucosal sensory nerve endings in mouth, pharynx, and stomach
H3C Parasympatholytics
N
OCH2OH
O C CH
O Scopolamine
H1-Antihistamines
CH3
CH O CH2 CH2 N
CH3
Diphenhydramine
Cl
Meclozine
CH N N CH2
CH3
|
Dopamine D2 antagonists |
|
||||
|
|
|
|
|
O |
H |
|
|
|
|
|
N |
|
|
|
|
|
|
|
|
H |
O |
|
|
|
N |
|
N |
|
|
|
|
|
|
|
N |
|
N |
|
|
Cl |
|
|
|
|
|
Domperidone |
|
H2N |
|
OCH3 |
|
|
|
|
|
|
|
|
|
|
C2H5 |
Cl |
|
C |
NH |
CH2 |
CH2 |
N |
|
|
O |
|
|
|
C2H5 |
Metoclopramide |
|
|
|
|
|
|
|
|
|
O |
|
CH2 |
CH3 |
|
|
|
|
|
||
|
|
|
|
|
N |
|
|
|
|
|
|
|
N |
Ondansetron |
|
N |
|
|
|
|
|
CH3 |
|
|
|
||
|
|
|
|
|
|
|
|
5-HT3-antagonist |
|
344 Therapy of Selected Diseases
Alcohol Abuse
Since prehistoric times, ethanol-containing beverages have enjoyed widespread use as a recreational luxury. What applies to any medicinal substance also holds for alcohol: the dose alone makes the poison (see p. 2). Excessive, long-term consumption of alcoholic drinks, or alcohol abuse, is harmful to the affected individual. Alcoholism must be considered a grave disorder that plays a major role in terms of numbers alone; for instance, in Germany 1 000 000 people are affected by this self-inflicted illness.
Ethanol is miscible with water and is well lipid-soluble, enabling it to penetrate easily through all barriers in the organism; the blood–brain barrier and the placental barrier are no obstacles. In liver cells, alcohol is broken down to acetic acid via acetaldehyde (A). Ethyl alcohol is never ingested as a chemically pure substance but in the form of an alcoholic beverage that contains flavoring agents and higher alcohols, depending on its origin. The effect desired by the consumer takes place in the brain: ethanol acts as a stimulant, it disinhibits, and it enhances sociability, as long as the beverage is enjoyed in moderate quantities. After higher doses, self-critical faculties are lost and motor function is impaired–the familiar picture of the drunk. Still higher doses induce a comatose state (caution: hypothermia and respiratory paralysis). The complex effects on the CNS cannot be ascribed to a simple mechanism of action. An inhibitory effect on the NMDA subtype of glutamate receptor appears to predominate.
In chronic alcohol abuse, mainly two organs are damaged:
1.In the liver, hepatocytes may initially undergo fatty degeneration, this process being reversible. With continued exposure, liver cells die and are replaced by connective tissue newly formed from myofibroblasts: liver cirrhosis. Hepatic blood flow is greatly reduced; the organ becomes unable to fulfill its detoxification
function (danger of hepatic coma). Collateral circulation routes develop (bleeding from esophageal varicose veins) with production of ascites. Alcoholic liver cirrhosis is a severe, mostly progressive disease that permits only symptomatic therapy (B).
2.The functional capacity of the brain is impaired. Irreversible damage may manifest in a measurable fallout of neuronal cell bodies. Often delirium tremens develops (usually triggered by alcohol withdrawal), whichcanbemanagedwithintensivetherapy (clomethiazole, haloperidol, among others). In addition, alcoholic hallucinations and Wernicke–Korsakow syndrome
occur. All of these are desolate states.
It must be pointed out specifically that alcohol abuse during pregnancy leads to (em- bryo–fetal alcohol syndrome (malformations, persistent intellectual deficits). This intrauterine intoxication is relatively common: one case per 1000 births (C).
Chronic alcohol abuse is an expression of true dependence. Thus, therapy of this addiction is dif cult and frequently without success. There is no pharmacotherapeutic silver bullet (the NMDA receptor antagonist acamprosate may be worth trying). Above all, psychotherapeutic care, a change in milieu, and supportive treatment with benzodiazepines are important.
Alcohol Abuse |
345 |
A. Alcoholism |
|
|
Ethanol |
Acetaldehyde |
Acetic acid |
H3C |
H3C |
H3C |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
H2COH |
|
HC=O |
|
COOH |
|
||||||
|
|
NAD+ |
NADH |
|
|
NAD+ |
NADH |
|
|
||
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
Main catabolic pathway of ethanol in liver cell
Quotient NADH/NAD+
Fatty acid oxidation Fatty acid synthesis Triglyceride synthesis
Fatty liver
Cell necroses
Cirrhosis
B. Liver cirrhosis |
|
|
Hepatic |
Esophageal and |
Ascites |
encepha- |
gastric varices |
|
lopathy |
|
|
Insufficient |
|
Portal |
presystemic |
|
hypertension |
elimination |
|
|
of NH3 |
|
|
|
|
Liver cirrhosis |
C. Embryo-fetal alcohol syndrome